Labo BNK, an innovative diagnostic laboratory testing services company announces the appointment of Dr. Peter Ross as Vice-President, Research and Development.
Online PR News – 23-May-2014 – Laval, Quebec , May 12, 2014 – Labo BNK, an innovative diagnostic laboratory testing services company is proud to announce the appointment of Dr. Peter Ross as Vice-President, Research and Development.
After completing his fellowship in clinical biochemistry, Dr. Ross began his career as a clinical biochemist at the Maisonneuve-Rosemont Hospital in Montreal, Quebec. As his career in the pharmaceutical industry progressed, he has gained extensive experience in clinical research and drug development. Dr. Ross has led local, national and international studies of phases 1 through 4 at some of the pharmaceutical industry’s leading companies including Wyeth, Pfizer and Axcan. He has held many senior positions where he has acquired a strong background in the management and monitoring of studies, clinical data management, samples logistics management in the area of innocuous diseases and the use of biomarkers.
From his early beginnings as a clinical scientist working in the field, Dr. Ross has held management positions at the national level and within international pharmaceutical companies. He also served as Senior Director of Clinical Operations and Head of the Laboratory Diagnosis of for contract pharmaceutical research and generic drug research companies. Dr. Ross adheres to the highest standards regarding the quality, time and cost as well as the regulatory, ethical and legal requirements governing the conduct of clinical trials. He firmly believes in the importance of each sample and test and those they must be delivered on time while maintaining the highest quality standards.
Labo BNK’s President and Scientific Director Dr. Gilles Brisson, PhD, CSPQ, FCACB was extremely pleased with the appointment mentioning that “We are delighted to have Peter join the team. His experience leading clinical studies, as well as leading the operations for a world class CRO will allow us to better tailor our clinical research service offering”
Dr. Ross will take up his new post immediately.